tirzepatide surpass trials SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Tirzepatide: How It's Used &
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



00243-1/asset/23df9500-d21e-4a61-9bfa-1536b8dc9f75/main.assets/gr4a_lrg.jpg)























